Vera Therapeutics, Inc.

VERASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1831828

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$78.2M	$78.2M	$69.0M	$22.5M	$45.2M
Operating Expenses	$102.0M	$102.0M	$90.9M	$34.4M	$52.2M
Operating Income (Loss)	-$102.0M	-$102.0M	-$90.9M	-$34.4M	-$52.2M
Interest Expense	—	—	$992.0K	$20.0K	$166.0K
Nonoperating Income (Expense)	$6.0M	$6.0M	$1.8M	$1.8M	-$1.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$96.0M	-$96.0M	-$89.1M	-$32.6M	-$53.4M
Income Tax Expense (Benefit)	$1.0K	$1.0K	$1.0K	$1.0K	-$1.0K
Net Income (Loss) Attributable to Parent	-$96.0M	-$96.0M	-$89.1M	-$32.6M	-$53.4M
Earnings Per Share, Basic	-$2.25	-$2.25	-$3.35	-$2.43	—
Earnings Per Share, Diluted	-$2.25	-$2.25	-$3.35	-$2.43	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$655.7M	$175.5M	$131.4M	$83.7M	$54.6M
Assets, Current	$651.2M	$172.0M	$125.7M	$82.5M	$54.3M
Cash and Cash Equivalents, at Carrying Value	$92.6M	$45.7M	$43.5M	$79.7M	$53.7M
Liabilities	$78.5M	$73.9M	$54.5M	$14.2M	$4.3M
Liabilities, Current	$25.4M	$22.3M	$25.6M	$7.7M	$2.4M
Long-term Debt	$50.7M	$49.9M	$24.8M	$4.9M	$0.00
Accounts Payable, Current	$7.7M	$11.1M	$12.0M	$1.4M	$909.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$92.2M	-$92.2M	-$67.6M	-$23.7M	-$34.8M
Net Cash Provided by (Used in) Investing Activities	-$39.4M	-$39.4M	-$70.6M	-$4.2M	-$42.0K
Net Cash Provided by (Used in) Financing Activities	$133.5M	$133.5M	$101.9M	$53.9M	$85.3M
Payments to Acquire Property, Plant, and Equipment	$63.0K	$63.0K	$62.0K	$0.00	$99.0K
Payments for Repurchase of Common Stock	$0.00	$0.00	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)